SUNNYVALE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that management will be participating in the Wells Fargo Virtual Healthcare Conference on Friday, September 10, 2021 at 8:20 a.m. Pacific Time / 11:20 a.m. Eastern Time.
Interested parties can access a live webcast of the presentation on the investors section of the company website at investors.23andme.com under the “News & Events” menu. The latest information on this and other events, including any changes to presentation dates and times, can also be found there. A webcast replay will be available at the same location for a limited time within 24 hours after the event.
About 23andMe
23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its nearly 12 million customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at www.23andMe.com.
Forward-Looking Statements
This press release contains certain “forward-looking statements” including the future performance of 23andMe’s businesses in consumer genetics and therapeutics and the growth and potential of its crowdsourced research platform. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained herein are based on 23andMe’s current expectations and beliefs concerning future developments and their potential effects, but there can be no assurance that these will be as anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Except as required by law, 23andMe does not undertake any obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.
Investor Relations Contact: investors@23andMe.com
Media Contact: press@23andMe.com
![](https://ml.globenewswire.com/media/ZjFhZjZiOTMtMzcxMC00ZDIxLThhNDQtMGQ1MmQ5NGIzYWZlLTEyMTk5OTY=/tiny/23andMe-Inc-.png)